IκBα kinase inhibitor IKI-1 conferred tumor necrosis factor α sensitivity to pancreatic cancer cells and a xenograft tumor model

Cancer Research

Volumn 68, Issue 22, 2008, Pages 9519-9524

  Zhang, Yixian ^a,b   Gavriil, Maria ^a   Lucas, Judy ^a   Mandiyan, Sreekala ^a   Follettie, Max ^a   Diesl, Veronica ^a   Sum, Fuk Wah ^a   Powell, Dennis ^a   Haney, Steve ^a   Abraham, Robert ^a   Arndt, Kim ^a  

^a WYETH RESEARCH   (United States)

^b Enzon Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; I KAPPA B KINASE; N (3 (DIMETHYLAMINO)PROPYL) 4 ((4 (3 FLUORO 4 METHOXYPHENYL)PYRIMIDIN 2 YL)AMINO)BENZENESULFONAMIDE; N-(3-(DIMETHYLAMINO)PROPYL)-4-((4-(3-FLUORO-4-METHOXYPHENYL)PYRIMIDIN-2-YL)AMINO)BENZENESULFONAMIDE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; DRUG ANTAGONISM; DRUG SCREENING; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PHOSPHORYLATION; PROTEIN TRANSPORT; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; HUMANS; I-KAPPA B KINASE; MICE; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; PYRIMIDINES; SULFONAMIDES; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 56449120810     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1549     Document Type: Article

References (35)

1. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-25.
2. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev 2003;14:185-91.
3. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117:244-79.
4. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-a in cancer. Curr Opin Immunol 1998;10:573-80.
5. Mocellin S, Rossi CR, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 2005;16:35-53.
6. Mocellin S, Pilati P, Nitti D. Towards the development of tumor necrosis factor (TNF) sensitizers: making TNF work against cancer. Curr Pharm Des 2007;13:537-51.
7. Tracey K. The acute and chronic pathophysiologic Effects. In: Beutler B, editor. Tumor necrosis factors: the molecules and their emerging role in medicine. New York: Raven Press; 1992. p. 255-73.
8. Malik S. The activity of TNF in experimental cancer models. In: Beutler B, editor. Tumor necrosis factors: the molecules and their emerging role in medicine. New York: Raven Press; 1992. p. 407-23.
9. MacEwan DJ. TNF ligands and receptors - a matter of life and death. Br J Pharmacol 2002;135:855-75.
10. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003;10:45-65.
11. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 2000;18:621-63.
12. Perkins ND. Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol 2007;8: 49-62.
13. Scheidereit C. IκB kinase complexes: gateways to NF-κB activation and transcription. Oncogene 2006;25:6685-705.
14. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996;274: 782-4.
15. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996;274:787-9.
16. Wang CY, Mayo MW, Baldwin AS, Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996;274:784-7.
17. Li YQ, Zhang ZX, Xu YJ, et al. N -Acetyl-L-cysteine and pyrrolidine dithiocarbamate inhibited nuclear factor-κB activation in alveolar macrophages by different mechanisms. Acta Pharmacol Sin 2006;27:339-46.
18. McDade TP, Perugini RA, Vittimberga FJ, Jr., Carrigan RC, Callery MP. Salicylates inhibit NF-κB activation and enhance TNF-α-induced apoptosis in human pancreatic cancer cells. J Surg Res 1999;83:56-61.
19. Oka S, Kamata H, Kamata K, Yagisawa H, Hirata H. N-acetylcysteine suppresses TNF-induced NF-κ B activation through inhibition of IκB kinases. FEBS Lett 2000; 472:196-202.
20. Sarkar A, Sreenivasan Y, Ramesh GT, Manna SK. β-D Glucoside suppresses tumor necrosis factor-induced activation of nuclear transcription factor κB but potentiates apoptosis. J Biol Chem 2004;279:33768-81.
21. Sethi G, Ahn KS, Pandey MK, Aggarwal BB. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NFκB-regulated gene products and TAK1-mediated NF-κB activation. Blood 2007;109:2727-35.
22. Zhang SY, Lin ZN, Yang CF, Shi XL, Ong CN, Shen HM. Suppressed NF-κ B and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-α-induced apoptosis in human cancer cells. Carcinogenesis 2004;25:2191-9.
23. Frelin C, Imbert V, Griessinger E, Loubat A, Dreano M, Peyron JF. AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-α in Jurkat leukemic cells. Oncogene 2003;22:8187-94.
24. Velasco AM, Gillis KA, Li Y, et al. Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology 2004;145:3913-24.
25. Sadler TM, Gavriil M, Annable T, Frost P, Greenberger LM, Zhang Y. Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus. Endocr Relat Cancer 2006;13:863-73.
26. Tse RV, Dawson LA, Wei A, Moore M. Neoadjuvant treatment for pancreatic cancer - a review. Crit Rev Oncol Hematol 2008;65:263-74.
27. Welsch T, Kleeff J, Friess H. Molecular pathogenesis of pancreatic cancer: advances and challenges. Curr Mol Med 2007;7:504-21.
28. Wolff RA. Chemotherapy for pancreatic cancer: from metastatic disease to adjuvant therapy. Cancer J 2007;13: 175-84.
29. Hines OJ, Reber HA. Pancreatic neoplasms. Curr Opin Gastroenterol 2004;20:452-8.
30. Fernandez-Zapico ME, Kaczynski JA, Urrutia R. Pancreatic cancer research: challenges, opportunities, and recent developments. Curr Opin Gastroenterol 2002; 18:563-7.
31. van Laarhoven HW, Gambarota G, Heerschap A, et al. Effects of the tumor vasculature targeting agent NGRTNF on the tumor microenvironment in murine lymphomas. Invest New Drugs 2006;24:27-36.
32. Van Ostade X, Vandenabeele P, Everaerdt B, et al. Human TNF mutants with selective activity on the p55 receptor. Nature 1993;361:266-9.
33. Chang KJ, Lee JG, Holcombe RF, Kuo J, Muthusamy R, Wu ML. Endoscopic ultrasound delivery of an antitumor agent to treat a case of pancreatic cancer. Nat Clin Pract Gastroenterol Hepatol 2008;5:107-11.
34. Chang KJ, Shen SY, Gu M, et al. Effect of TNFerade local gene therapy on expression of tumor necrosis factor a (TNF-α) and survivin in tumors of patients with pancreatic cancer: can we prove and predict response to therapy? Gastroenterology 2004;126:A623.
35. Paciotti GF, Kingston DGI, Tamarkin L. Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor-targeted drug delivery vectors. Drug Dev Res 2006;67:47-54.